TCL Archive Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint November 25, 2011
TCL Archive ODAC Recommends TICE BCG Approval For Recurrent Bladder Cancer Prevention January 10, 1997